Recursion Pharmaceuticals (RXRX) Payables (2020 - 2026)

Recursion Pharmaceuticals has reported Payables for 7 years, with the latest figure at $20.3 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 18.89% year-over-year to $20.3 million; the trailing twelve-month figure through Mar 2026 stood at $20.3 million (down 18.89% YoY), and the FY2025 full-year result was $18.1 million, down 16.17% from the prior year.
• Payables for Q1 2026 stood at $20.3 million, up from $18.1 million in the prior quarter.
• The five-year high for Payables was $25.1 million in Q1 2025, with the low at $2.3 million in Q3 2024.
• Historically, Payables has averaged $9.6 million across 5 years, with a median of $4.9 million in 2023.
• Annual changes were most pronounced in 2024 — Payables sank 54.44% — and 2025, when it soared 516.59%.
• Recursion Pharmaceuticals' Payables stood at $4.7 million in 2022, then fell by 14.71% to $4.0 million in 2023, then soared by 441.14% to $21.6 million in 2024, then retreated by 16.17% to $18.1 million in 2025, then increased by 12.31% to $20.3 million in 2026.
• The last three Payables figures came in at $20.3 million (Q1 2026), $18.1 million (Q4 2025), and $13.9 million (Q3 2025), per Business Quant data.